Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Japan Ethical Drug Sales Up 0.8% in December: Crecon
February 8, 2024
- 2,000 Patients Receiving Leqembi in US, 4 Times the Number on Wait List: Eisai
February 7, 2024
- CEO Bids Farewell to Mitsubishi Chemical after Group Revamp
February 7, 2024
- Keytruda Tops Japan Sales Ranking for 4th Month in January: Encise
February 7, 2024
- Sumitomo to Reinforce Restructuring to Fight Deficit, First in North America: President
February 6, 2024
- Astellas Slashes FY2023 Veozah Forecast as Vertical Start-Up Plan Stumbles
February 6, 2024
- Chugai’s 2023 Earnings Slip as Ronapreve Wanes, but Sales Still Top 1 Trillion Yen
February 2, 2024
- Chugai to Make Singapore Unit a Permanent Drug Discovery Research Base
February 2, 2024
- Takeda’s April-December Sales Up 4.6%, but Flat at CER
February 2, 2024
- Takeda Bags Global Rights to Protagonist’s Rare Hematology Asset
February 2, 2024
- Milano Furuta to Take Over as CFO of Takeda in April
February 2, 2024
- Cheplapharm Takes Over Xeloda from Chugai in Japan
February 2, 2024
- Cefiderocol Approved for Use in China’s Special Medical Tourism Zone: Shionogi
February 2, 2024
- Shionogi Sees 60% Ramp-Up in Medicon Output in FY2023
February 2, 2024
- Sumitomo to Cut Med- to Long-Term Guidance amid Tepid Uptake of New Drivers
February 1, 2024
- Astellas Links Arms with Mass General Brigham for Early R&D
February 1, 2024
- BMS Files Breyanzi in Japan for Expanded Use in Follicular Lymphoma
February 1, 2024
- Daiichi Sankyo Ups Full-Year Outlook on Growth of Flu, COVID Products
February 1, 2024
- Daiichi Sankyo Seeks Label Expansion for Ezharmia into PTCL in Japan
February 1, 2024
- Keytruda/Padcev Filed in Japan for 1st Line Bladder Cancer Treatment: MSD, Astellas
February 1, 2024
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…